Incyte INCY

equity

Price History

The shaded fan is where this price has historically travelled over the months after a close like today’s. It is not a forecast: it has no view on direction, only on distance.

2021-102026-09 · $125.31

Range of outcomes, looking ahead3 months

Over 3 months from Sep 2026, roughly two-thirds of past moves landed between $110.26 and $142.42; nine in ten between $101.52 and $154.67.

Tested against this asset’s own history: across 380 past 3-month windows, the price actually landed inside the two-thirds band 71% of the time. The gap from 68% is the model’s error — real returns have fatter tails than the maths assumes, so the band gets breached more often than it claims.

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

1993-112026-09 · -9.1%

Worst drawdown: −98%, peaking Feb 2000 and bottoming Feb 2009 — still unrecovered after 319 months.

DCA Backtest

Start month

Monthly amount (USD)

Invested: $39,500
Value today: $436,682
Return: +1005.5%
Months invested: 395

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $62,641 today, so the real (inflation-adjusted) return is +597.1%.

Lump sum instead — $39,500 all at once in Nov 1993: $2,199,887 (+5469.3%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Feb 2000): $282,159 on $32,000 invested (+781.7%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

	J	F	M	A	M	J	J	A	S	O	N	D
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1993-11: +1005.5%

About Incyte

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. (Wikipedia)

It's a listed company categorised under health care and biotechnology, with a market cap of about $25.4B.

It rates Extreme Risk at 3.3/5, meaning the rated factors are poor across the board — treat any position here as speculative.

What pushes the score up: earnings quality (5.0/5) and market / volatility (4.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: leverage / financial, concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Extreme Risk(3.3/5)60% rated

How these ratings work

Market / Volatility4.0/5 · weight 20%

Annualised volatility (3yr)3/525.6
Max drawdown from ATH5/598.3
Beta vs S&P 5004/51.4

Liquidity1.0/5 · weight 15%

Avg daily $ volume1/5219.7m
Float % of shares outstandingnot yet researched

Leverage / Financialunrated · weight 20%

Debt / equitynot yet researched
Interest coverage (EBIT / interest)not yet researched

Earnings Quality5.0/5 · weight 15%

3yr EPS volatility5/53,018

Concentrationunrated · weight 10%

Largest customer, % of revenuenot yet researched
Geographic revenue concentrationnot yet researched

Governanceunrated · weight 10%

Board independence %not yet researched
Share structurenot yet researched
Litigation / audit historynot yet researched

Sector / Regulatory3.0/5 · weight 10%

Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.